A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) ...
2024-02-01
عنوان الدراسة
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD
داعم الدراسة
Boehringer
دواء الدراسة
BI 456906
رقم بروتوكول الدراسة
1404-0040
حالة الدراسة
Ongoing
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh) , King Fahad Specialist Hospital (Dammam), King Abdulaziz University Hospital (Jeddah),King Saud Medical City (Riyadh)
مرحلة الدراسة
3
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.